Home>SERVICES > Dyslipidemia

SERVICES

Dyslipidemia
PriMed Non-human Primate Model of Dyslipidemia and Atherosclerosis

Nonhuman primates are phylogenetically similar to humans including in lipid metabolism and lipid profiles. All humans and NHPs are susceptible to the development of diabetes and dyslipidemia from middle age.


Primed Spontaneous Dyslipidemia NHP Capability

Breeding center: n=~3000 rhesus macaques (macaca mulatta).
Colony of n=~700 dysmetabolic rhesus macaques.
Historical clinical /metabolic data (8yrs.)
Semiannual metabolic screenings.
Plasma and tissue biobank.


Benchmark Study:

PCSK9 inhibitor, Ezetimibe and statins have been validated with our dyslipidemia NHP model.
Metabolic biomarker assay development and validation (HMG-COA reductase inhibitors, PCSK9 inhibitors, NPC1L1).
More than 40 compounds have been performed for a dozen international and domestic clients.


Connect